{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/collaborative-practices-advance-rare-ophthalmological-disease-clinical-trial#webpage",
"url": "https://www.fortrea.com/insights/collaborative-practices-advance-rare-ophthalmological-disease-clinical-trial",
"name": "Collaborative practices advance a rare ophthalmological disease clinical trial",
"description": "Explore how rare ophthalmological disease clinical trials require collaborative strategies to overcome recruitment challenges and deliver successful outcomes. Learn how rare disease patient recruitment is strengthened through engagement with advocacy groups, improved study visibility, and targeted outreach. Explore how strong site relationships and frequent communication across global clinical trial sites enhance transparency, enable better enrollment tracking, and support informed decision-making. Learn how collaboration between sponsors, CRO teams, and sites helps address the complexities of ultra-rare disease studies and improves overall trial execution. By integrating patient-centric approaches, advocacy partnerships, and operational expertise, rare ophthalmological disease clinical trials can exceed recruitment targets and accelerate clinical development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Collaborative practices advance a rare ophthalmological disease clinical trial",
"item": "https://www.fortrea.com/insights/collaborative-practices-advance-rare-ophthalmological-disease-clinical-trial"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/collaborative-practices-advance-rare-ophthalmological-disease-clinical-trial#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/collaborative-practices-advance-rare-ophthalmological-disease-clinical-trial#webpage"
},
"headline": "Rare Ophthalmological Disease Clinical Trial and Patient Recruitment Success | Fortrea Case Study",
"description": "Explore how rare ophthalmological disease clinical trials require collaborative strategies to overcome recruitment challenges and deliver successful outcomes. Learn how rare disease patient recruitment is strengthened through engagement with advocacy groups, improved study visibility, and targeted outreach. Explore how strong site relationships and frequent communication across global clinical trial sites enhance transparency, enable better enrollment tracking, and support informed decision-making. Learn how collaboration between sponsors, CRO teams, and sites helps address the complexities of ultra-rare disease studies and improves overall trial execution. By integrating patient-centric approaches, advocacy partnerships, and operational expertise, rare ophthalmological disease clinical trials can exceed recruitment targets and accelerate clinical development.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/rare-ophthalmological-disease-clinical-trial.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-15",
"dateModified": "2025-02-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-01/rare-ophthalmological-disease-case-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}